BR112021009653A2 - método para administrar um corticosteroide a um paciente em necessidade do mesmo, método para reduzir ou prevenir os efeitos colaterais associados à administração de corticosteroides a um paciente em necessidade do mesmo, e produto farmacêutico - Google Patents

método para administrar um corticosteroide a um paciente em necessidade do mesmo, método para reduzir ou prevenir os efeitos colaterais associados à administração de corticosteroides a um paciente em necessidade do mesmo, e produto farmacêutico Download PDF

Info

Publication number
BR112021009653A2
BR112021009653A2 BR112021009653-1A BR112021009653A BR112021009653A2 BR 112021009653 A2 BR112021009653 A2 BR 112021009653A2 BR 112021009653 A BR112021009653 A BR 112021009653A BR 112021009653 A2 BR112021009653 A2 BR 112021009653A2
Authority
BR
Brazil
Prior art keywords
corticosteroid
dose
urine
hsd1 inhibitor
patient
Prior art date
Application number
BR112021009653-1A
Other languages
English (en)
Portuguese (pt)
Inventor
David A. Katz
Original Assignee
Sparrow Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sparrow Pharmaceuticals, Inc. filed Critical Sparrow Pharmaceuticals, Inc.
Publication of BR112021009653A2 publication Critical patent/BR112021009653A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112021009653-1A 2018-11-20 2019-08-14 método para administrar um corticosteroide a um paciente em necessidade do mesmo, método para reduzir ou prevenir os efeitos colaterais associados à administração de corticosteroides a um paciente em necessidade do mesmo, e produto farmacêutico BR112021009653A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862769932P 2018-11-20 2018-11-20
US62/769,932 2018-11-20
PCT/US2019/046449 WO2020106337A1 (en) 2018-11-20 2019-08-14 Methods for administering corticosteroids

Publications (1)

Publication Number Publication Date
BR112021009653A2 true BR112021009653A2 (pt) 2021-08-17

Family

ID=70774135

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021009653-1A BR112021009653A2 (pt) 2018-11-20 2019-08-14 método para administrar um corticosteroide a um paciente em necessidade do mesmo, método para reduzir ou prevenir os efeitos colaterais associados à administração de corticosteroides a um paciente em necessidade do mesmo, e produto farmacêutico

Country Status (10)

Country Link
US (2) US12220412B2 (https=)
EP (1) EP3883578A4 (https=)
JP (2) JP7472122B2 (https=)
CN (1) CN113329754A (https=)
AU (2) AU2019384074B2 (https=)
BR (1) BR112021009653A2 (https=)
CA (1) CA3120339A1 (https=)
IL (2) IL283069B2 (https=)
MX (2) MX2021005801A (https=)
WO (1) WO2020106337A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022076398A1 (en) * 2020-10-07 2022-04-14 Surface Ophthalmics, Inc. Pharmaceutical kits and their use for treating dry eye disease
CN113329754A (zh) 2018-11-20 2021-08-31 麻雀制药股份有限公司 用于施用皮质类固醇的方法
CA3124945A1 (en) 2018-12-27 2020-07-02 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
BR112021015481A2 (pt) * 2019-02-08 2021-12-07 Sanofi Sa Otimização biotecnológica de micro-organismos para a 1,2-desidrogenação de esteroides
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
US12310981B2 (en) 2021-05-10 2025-05-27 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
WO2023225507A1 (en) * 2022-05-16 2023-11-23 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid excess
EP4525983A4 (en) * 2022-05-16 2025-09-03 Sparrow Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS
AU2024348222A1 (en) * 2023-09-27 2026-04-16 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid-mediated diseases
GB202408335D0 (en) 2024-06-11 2024-07-24 Astrazeneca Ab Therapies for wound treatment

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907821A (en) 1974-11-20 1975-09-23 Upjohn Co 2-{8 3-{8 1-(DIMETHYLAMINO)CYCLOPROPYL{8 -4H-1,2,4-triazol-4-yl{8 {0 benzophenone
US4577020A (en) 1983-01-25 1986-03-18 The Upjohn Company Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents
IL84093A (en) 1986-10-09 1992-09-06 Ciba Geigy Ag Aralkyl-4h-1,2,4-triazole derivatives,their preparation and pharmaceutical compositions containing them
GB0101447D0 (en) * 2001-01-19 2001-03-07 Univ Edinburgh Regulation of glucocorticoid concentration
GB0107383D0 (en) 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
AUPR878201A0 (en) 2001-11-09 2001-12-06 Fujisawa Pharmaceutical Co., Ltd. New compounds
WO2003059267A2 (en) 2001-12-21 2003-07-24 Rhode Island Hospital SELECTIVE 11β-HSD INHIBITORS AND METHODS FOR USE THEREOF
WO2003065983A2 (en) 2002-02-01 2003-08-14 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
IL166510A0 (en) 2002-08-09 2006-01-15 Nps Pharma Inc 1,2,4"oxadiazole as modulators of metabotropic glutamate receptor-5
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
ATE467616T1 (de) 2003-04-11 2010-05-15 High Point Pharmaceuticals Llc Verbindungen mit aktivität an der 11beta- hydroxasteroiddehydrogenase
US20060094699A1 (en) * 2003-04-11 2006-05-04 Kampen Gita Camilla T Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
WO2004089367A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
DE602004025220D1 (de) 2003-04-11 2010-03-11 High Point Pharmaceuticals Llc Pharmazeutische verwendungen von kondensierten 1,2,4-triazolen
US8026264B2 (en) 2003-05-29 2011-09-27 Merck Sharp And Dohme Corp. Triazole derivatives as inhibitors of 11-β hydroxysteroid dehydrogenase-1
AU2004286836A1 (en) 2003-10-28 2005-05-19 Amgen Inc. Triazole compounds and uses related thereto
JP2005170939A (ja) 2003-11-20 2005-06-30 Takeda Chem Ind Ltd 糖尿病の予防・治療剤
AP2006003633A0 (en) 2003-12-19 2006-06-30 Pfizer Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-BETA-hydroxysteroid dehydrogenase type 1 (11-BETA-HSD-1) for the treatment of diabetes and obesity
US7507832B2 (en) 2003-12-22 2009-03-24 Eli Lilly And Company Triazole PPAR modulators
AU2005230864A1 (en) 2004-03-29 2005-10-20 Merck Sharp & Dohme Corp. Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
US8415354B2 (en) 2004-04-29 2013-04-09 Abbott Laboratories Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US7880001B2 (en) 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US8022225B2 (en) 2004-08-04 2011-09-20 Taisho Pharmaceutical Co., Ltd Triazole derivative
JP4882748B2 (ja) 2004-09-16 2012-02-22 アステラス製薬株式会社 トリアゾール誘導体またはその塩
JP2008518903A (ja) 2004-11-02 2008-06-05 ファイザー・インク 置換および非置換アダマンチルアミドの新規化合物
WO2006068199A1 (ja) 2004-12-22 2006-06-29 Mochida Pharmaceutical Co., Ltd. 代謝的に安定な３－オキシ－１，２，４－トリアゾール誘導体
WO2006080533A1 (ja) 2005-01-31 2006-08-03 Mochida Pharmaceutical Co., Ltd. ３－アミノ－１,２,４－トリアゾール誘導体
WO2006134481A1 (en) 2005-06-16 2006-12-21 Pfizer Inc. Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1
CN101198605A (zh) 2005-06-16 2008-06-11 辉瑞大药厂 N-(吡啶-2-基)-磺酰胺衍生物
AU2006257646A1 (en) 2005-06-16 2006-12-21 Pfizer Inc. N-(pyridin-2-YL)-sulfonamide derivatives
WO2007007688A1 (ja) 2005-07-08 2007-01-18 Mochida Pharmaceutical Co., Ltd. ３,５－ジアミノ－１,２,４－トリアゾール誘導体
JP5261176B2 (ja) 2005-08-16 2013-08-14 アイカジェン， インコーポレイテッド 電位作動型ナトリウムチャンネル阻害剤
AR058807A1 (es) 2005-09-29 2008-02-27 Astrazeneca Ab 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5
BRPI0708782A2 (pt) 2006-03-16 2011-06-14 Astellas Pharma Inc derivado de triazol ou um sal deste
US20070224298A1 (en) 2006-03-23 2007-09-27 Talbott Shawn M Inhibiting 11(beta)-hsd1 with citrus flavonoids
US7435833B2 (en) 2006-04-07 2008-10-14 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
WO2010001946A1 (ja) 2008-07-03 2010-01-07 アステラス製薬株式会社 トリアゾール誘導体またはその塩
EP2243494A1 (en) * 2009-04-22 2010-10-27 OntoChem GmbH Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist.
WO2011068927A2 (en) * 2009-12-04 2011-06-09 Abbott Laboratories 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF
GB201003734D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
UA112418C2 (uk) * 2010-09-07 2016-09-12 Астеллас Фарма Інк. Терапевтичний болезаспокійливий засіб
SG11201405214YA (en) * 2012-03-13 2014-10-30 Abbvie Inc Method for selecting or identifying a subject for v1b antagonist therapy
CN106659723A (zh) * 2014-07-09 2017-05-10 爱普制药有限责任公司 用于治疗神经病症的方法
US10894054B2 (en) 2015-04-07 2021-01-19 Intercept Pharmaceuticals, Inc. FXR agonist compositions for combination therapy
US10648506B2 (en) 2016-07-07 2020-05-12 Raul Mendoza Walking rig creeper interface
WO2018117063A1 (ja) 2016-12-20 2018-06-28 アステラス製薬株式会社 焦燥性興奮治療剤
CN113329754A (zh) 2018-11-20 2021-08-31 麻雀制药股份有限公司 用于施用皮质类固醇的方法
EP3821892A1 (en) 2019-11-12 2021-05-19 University of Leeds (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl) acetic acid for use in treating wounds
EP3878446A1 (en) 2020-03-09 2021-09-15 Universite De Geneve Hsd11b1 inhibitors for use in immunotherapy and uses thereof
EP4525983A4 (en) 2022-05-16 2025-09-03 Sparrow Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS
WO2023225507A1 (en) 2022-05-16 2023-11-23 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid excess

Also Published As

Publication number Publication date
IL283069B2 (en) 2025-09-01
EP3883578A4 (en) 2022-07-27
CA3120339A1 (en) 2020-05-28
JP2024098991A (ja) 2024-07-24
MX2025002836A (es) 2025-04-02
WO2020106337A1 (en) 2020-05-28
IL283069B1 (en) 2025-05-01
JP2022507103A (ja) 2022-01-18
JP7472122B2 (ja) 2024-04-22
MX2021005801A (es) 2021-08-05
IL319327A (en) 2025-05-01
US12220412B2 (en) 2025-02-11
EP3883578A1 (en) 2021-09-29
AU2019384074A1 (en) 2021-06-03
US20250205227A1 (en) 2025-06-26
US20210393622A1 (en) 2021-12-23
IL283069A (en) 2021-06-30
AU2025203033A1 (en) 2025-05-22
AU2019384074B2 (en) 2025-04-10
CN113329754A (zh) 2021-08-31

Similar Documents

Publication Publication Date Title
BR112021009653A2 (pt) método para administrar um corticosteroide a um paciente em necessidade do mesmo, método para reduzir ou prevenir os efeitos colaterais associados à administração de corticosteroides a um paciente em necessidade do mesmo, e produto farmacêutico
US20220249515A1 (en) Ganaxolone for use in treating genetic epileptic disorders
Kundhal et al. Controlled ileal release budesonide in pediatric Crohn disease: efficacy and effect on growth
CA2640484A1 (en) Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
JP2022507103A5 (https=)
CN105358160A (zh) 亚硝酸盐的药物制剂及其用途
JP2022031479A (ja) アルツハイマー病治療に関連するアミロイド関連画像異常の治療または予防方法
KR20130099815A (ko) 글루코코르티코이드에 기초한 조성물의 약량학 및 투여
KR20200062241A (ko) 시포니모드의 투여 요법
JP2019507786A (ja) 慢性閉塞性肺疾患の急性増悪の治療のための投与レジメン
US11571412B2 (en) Thromboxane receptor antagonists in AERD/asthma
WO2019004465A1 (ja) ペマフィブラートを含有する医薬
JP2023503928A (ja) 結節性硬化症の治療での使用のためのガナキソロン
JP2019001830A (ja) 医薬
EP4019016A1 (en) Methods of administering intravenous baclofen
BR112021014593A2 (pt) Composições de metilfenidato para tratamento de transtorno de déficit de atenção e hiperatividade
EA051671B1 (ru) Ганаксолон для использования в лечении комплекса туберозного склероза
EA052165B1 (ru) Ганаксолон для использования в лечении наследственных эпилептических заболеваний

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]